Promyelocytic leukemia protein: an atherosclerosis suppressor protein?
Clin Sci (Lond)
; 135(13): 1557-1561, 2021 07 16.
Article
in En
| MEDLINE
| ID: mdl-34192313
ABSTRACT
As many as 70% of cells in atherosclerotic plaque are vascular smooth muscle cell (VSMC) in origin, and pathways and proteins which regulate VSMC migration, proliferation, and phenotype modulation represent novel targets for rational drug design to reduce atherosclerotic vascular disease. In this volume of Clinical Science, Karle et al. demonstrate that tumor suppressor, promyelocytic leukemia protein (PML) plays an important role in regulation of VSMC phenotype and response to inflammatory stimuli (Clin Sci (2021) 135(7), 887-905; DOI 10.1042/CS20201399). This important work demonstrates that PML, previously unrecognized as a participant in development of atherosclerosis, may represent a novel target for anti-atherosclerotic therapeutic modalities.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Atherosclerosis
/
Plaque, Atherosclerotic
Limits:
Humans
Language:
En
Journal:
Clin Sci (Lond)
Year:
2021
Document type:
Article
Affiliation country:
United States